http://www.kidney-international.org & 2013 KDIGO viii Kidney International Supplements (2013) 3, viii CONVERSION FACTORS OF CONVENTIONAL UNITS TO SI UNITS Parameter Conventional unit Conversion factor SI units Cholesterol (total, HDL-C, LDL-C) mg/dl 0.0259 mmol/l Creatinine (serum, plasma) mg/dl 88.4 mmol/l Triglycerides (serum) mg/dl 0.0113 mmol/l Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Note: Conventional unit  conversion factor SI unit. Kidney International Supplements (2013) 3, ix ix http://www.kidney-international.org & 2013 KDIGO x Kidney International Supplements (2013) 3, x Abbreviations and Acronyms 4D Die Deutsche Diabetes Dialyse Studie ACCORD Action to Control Cardiovascular Risk in Diabetes trial AGREE Appraisal of Guidelines for Research and Evaluation ALERT Assessment of Lescol in Renal Transplantation trial ALLHAT Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial ALLIANCE Aggressive Lipid Lowering Initiation Abates New Cardiac Events trial ApoB Apolipoprotein B ASPEN Atorvastatin as Prevention of Coronary Heart Disease Endpoints in Patients with Non-Insulin- Dependent Diabetes Mellitus trial ASSIGN ASSessing cardiovascular risk using SIGN guidelines ATP Adult Treatment Panel AURORA A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events CARDS Collaborative Atorvastatin Diabetes Study CARE Cholesterol and Recurrent Events trial CHD Coronary heart disease CI Confidence interval CK Creatine kinase CKD Chronic kidney disease CKiD Chronic Kidney Disease in Children study COGS Conference on Guideline Standardization CPG Clinical practice guideline CVD Cardiovascular disease DAIS Diabetes Atherosclerosis Intervention Study eGFR Estimated glomerular filtration rate ERT Evidence review team ESRD End-stage renal disease FIELD Fenofibrate Intervention and Event Lowering in Diabetes trial GFR Glomerular filtration rate GRADE Grading of Recommendations Assessment, Develop- ment, and Evaluation HD Hemodialysis HDL-C High-density lipoprotein cholesterol HR Hazard ratio IDEAL Incremental Decrease in Endpoints Through Aggressive Lipid Lowering trial KDIGO Kidney Disease: Improving Global Outcomes KDOQI Kidney Disease Outcomes Quality Initiative LDL-C Low-density lipoprotein cholesterol Lp(a) Lipoprotein(a) MI Myocardial infarction NKF National Kidney Foundation PDAY Pathobiological Determinants of Atherosclerosis in Youth study PICODD Population, Intervention, Comparator, Outcome, study Design and Duration of follow-up PREVEND IT Prevention of REnal and Vascular ENdstage Disease Intervention Trial PROCAM Prospective Cardiovascular Mu nster PROSPER Prospective Study of Pravastatin in the Elderly at Risk trial PROVE IT Pravastatin or Atorvastatin in Evaluation and Infec- tion Therapy trial QRISK2 QRISK cardiovascular disease risk algorithm RCT Randomized controlled trial RR Relative risk SCORE Systematic Coronary Risk Evaluation Project SCr Serum creatinine SEARCH Study Evaluating Additional Reductions in Choles- terol and Homocysteine SHARP Study of Heart and Renal Protection trial SPARCL Stroke Prevention by Aggressive Reduction in Choles- terol Levels trial TC Total cholesterol TG Triglyceride TLC Therapeutic lifestyle changes TNT Treating to New Targets trial VA-HIT Veterans Affairs high-density lipoprotein interven- tion trial http://www.kidney-international.org & 2013 KDIGO Notice SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE This Clinical Practice Guideline document is based upon systematic literature searches last conducted in August 2011, supplemented with additional evidence through June 2013. 